Key Highlights
- Elizabeth Galle joins AVS with over two decades of experience in the medical device sector, notably as VP of Global Clinical Research at CVRx.
- AVS is at the forefront of innovative treatment for calcified arterial disease with its Pulse™ IVL System.
- The company recently showcased positive first-in-human data at TCT 2024, underlining the safety and efficacy of its technology.
Source: Business Wire
Notable Quotes
- “In a time of significant growth and innovation at AVS, we are excited to welcome Liz to our executive leadership team,” – Mark Toland, Chairman of the Board at AVS
- “AVS has emerged as a pioneer in an exciting and novel area in medicine, intravascular lithotripsy,” – Elizabeth Galle, Vice President of Clinical Affairs at AVS
SoHC's Take
Elizabeth Galle’s rich background in global clinical research and her strategic leadership roles at CVRx and Boston Scientific make her an invaluable asset to AVS as the company navigates through crucial clinical and regulatory milestones. Her expertise in leading clinical strategies, combined with AVS’s innovative approach to treating calcified arterial disease, positions the company for significant advancements in the medical device industry. The recent TCT 2024 presentation further validates the potential of the Pulse™ IVL System to redefine interventional therapy, signaling promising developments for both peripheral and coronary treatments. AVS’s commitment to innovation and excellence in clinical affairs is well underscored by this strategic appointment, indicating a bright future for PIVL™ therapy and for patients suffering from severely calcified arterial disease.
